Researchers unravel important role of Rb tumor suppressor in aggressive form of breast cancer

December 4, 2013

The retinoblastoma (Rb) protein plays a critical role in suppressing the multi-step process of cell migration through the bloodstream, lymphovascular invasion and the metastasis of an aggressive type of breast cancer to the lung, researchers at the University of Cincinnati (UC) Cancer Institute, the Cincinnati Cancer Center (CCC) and the UC Brain Tumor Center have found.

The findings of Rb's role at multiple points in the disease process point to a potential new therapeutic target in patients with the most aggressive subset of breast , known as basal-like breast carcinomas. This type of cancer has no estrogen receptor expression, and to date there is no efficient therapy for patients who suffer from it, leaving them with a generally poor prognosis. Basal-like breast carcinomas spread to the lungs in about 25 percent of cases and to the brain in about 30 percent of cases.

The findings are published online in the journal PLOS ONE. The investigator-initiated research was funded by the UC Department of Cancer Biology's Startup Fund, the UC Dean's Fund and the Mayfield Education and Research Foundation.

"Our research suggests that Rb inhibits collective , which in turn inhibits the lymphovascular invasion, the release of cancer cells into the blood circulation and the growth of metastasis," says Samuel Godar, PhD, who led the study while an assistant professor in the Department of Cancer Biology. Godar is now visiting assistant professor of at UC and president of BioTest4U, a biotech startup based in Loveland, Ohio, and Covington, Ky.

The deadly progression begins when decreased levels of Rb are coupled with an increase in the expression of an oncoprotein (a gene that has the potential to cause cancer) called CD44. Basal-like breast carcinomas are known to have an elevated expression of CD44 and relatively low levels of Rb. Expression of the oncoprotein CD44 is required for the cells to move actively through the bloodstream.

The researchers studied Rb in two different ways. They studied its ability to suppress collective cell migration in cultures at the Vontz Center for Molecular Studies. They also studied Rb in an animal model, examining its ability to suppress the release of single and cancer cell clusters into the bloodstream.

"Our results suggest that Rb suppression stimulates an array of pathological consequences," says co-investigator James Driscoll, MD, PhD, assistant professor in the UC Department of Internal Medicine's Division of Hematology Oncology and member of the CCC. "It stimulates collective rather than single cell-based invasion and migration; it leads to lymphovascular invasion; and it orchestrates metastasis to remote organs through the bloodstream."

The research illuminates the crucial role of the Rb/CD44 pathway in the metastatic progression of basal-like breast carcinomas, Godar says.

"It points to the Rb/CD44 pathway as a promising target for therapy to combat the propensity for these aggressive breast cancers to metastasize to the lung and brain. About 90 percent of cancer patients die primarily because of metastatic disease. We believe that the complex analysis of metastatic progression in a preclinical model, such as the analysis we used, will become essential for predicting the true powers of novel anti-cancer drugs."

Explore further: Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy

More information: dx.plos.org/10.1371/journal.pone.0080590

Related Stories

Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy

July 26, 2012
Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel ...

New study shows insight into breast cancer cell migration

October 29, 2013
(Medical Xpress)—A new study by University of Kentucky Markey Cancer Center researchers Min Chen and Kathleen O'Connor shows that a specific protein may assist breast cancer cells in metastasizing.

Obesity found to be major risk factor in developing basal-like breast cancer

November 18, 2013
Women who are obese face an increased risk of developing an aggressive sub-type of breast cancer known as 'basal-like', according to research conducted at the University of North Carolina.

SABCS: Loss of RB in triple negative breast cancer associated with favorable clinical outcome

December 9, 2011
Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with ...

Team finds potential cause for deadly breast cancer relapse

November 25, 2013
Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways ...

Researchers find potential target for treating metastatic cancer

December 13, 2011
Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an ...

Recommended for you

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.